This is a prospective, randomized, multicenter, dose escalation study to determine subject safety, pharmacokinetic, and pharmacodynamic responses in patients with SPMS

This study is a prospective, randomized, placebo-controlled, blinded, dose escalation study of 3 to 4 cohorts with defined number of patients per cohort receiving active drug or placebo for a period of 4 months followed by safety monitoring for an additional 4 months after the last dose

Inclusion Criteria:

• A diagnosis of Secondary Progressive Multiple Sclerosis
• Aged 18 to 57 years old, at the time of informed consent

Exclusion Criteria:

• History of clinically important (as determined by the investigator) cardiac, endocrinologic, pulmonary, neurologic, immune, psychiatric, hepatic, renal or hematologic insufficiency or any other major disease other than MS ( Multiple Sclerosis)
• Inability in the opinion of the Investigator to comply with study requirements
• Other protocol-defined criteria may apply